title: HIV type 1 Gag as a target for antiviral therapy.
abstract: The Gag proteins of HIV-1 are central players in virus particle assembly, release, and maturation, and also function in the establishment of a productive infection. Despite their importance throughout the replication cycle, there are currently no approved antiretroviral therapies that target the Gag precursor protein or any of the mature Gag proteins. Recent progress in understanding the structural and cell biology of HIV-1 Gag function has revealed a number of potential Gag-related targets for possible therapeutic intervention. In this review, we summarize our current understanding of HIV-1 Gag and suggest some approaches for the development of novel antiretroviral agents that target Gag.
authors.affiliation: Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland 21702-1201, USA. waheedab@mail.nih.gov
authors.forename: Abdul A
authors.initials: AA
authors.lastname: Waheed
authors.forename: Eric O
authors.initials: EO
authors.lastname: Freed
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D055808:Drug Discovery; D015699:HIV Envelope Protein gp120 / Q000037:antagonists & inhibitors*; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D014157:Transcription Factors / Q000037:antagonists & inhibitors*; D014779:Virus Replication / Q000187:drug effects*; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000037:antagonists & inhibitors*
chemical_list: D019380:Anti-HIV Agents; D015699:HIV Envelope Protein gp120; D014157:Transcription Factors; D054301:gag Gene Products, Human Immunodeficiency Virus